Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Barclays PLC (BCS) vs TG Therapeutics Inc (TGTX) Price & Performance

Barclays PLCTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Barclays PLC vs TG Therapeutics Inc — how do they compare? Barclays PLC trades at $28.12 (market cap $93.87B), while TG Therapeutics Inc trades at $49.7 (market cap $7.64B). The key difference: Barclays PLC is far larger — about 12.3× TG Therapeutics Inc's market cap, and Barclays PLC pays a 2.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.

BCSTGTX
Market Cap
$93.87B$7.64B
Sector
FinancialsHealth
52-Week High
$28.56$59.06
52-Week Low
$19.36$26.94
Dividend Yield
2.19%
Enterprise Value
$7.84B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Barclays PLC

Barclays PLC (BCS) trades at $28.08, up 0.36% today, with a bullish technical signal from moving averages and a P/B ratio below 1 at 0.88, indicating potential undervaluation. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.90 surpassing the $0.89 estimate, while revenue growth accelerated to $29.14 billion in 2025. However, the stock faces headwinds from a securities class action investigation and concerns over cost pressures highlighted in recent analyst reports.

The outlook for BCS is cautiously optimistic, supported by strong profitability with a net income margin of 25.51% and analyst consensus favoring Buy ratings (68%). Key risks include ongoing legal scrutiny and rising operating expenses, but the stock's low valuation and dividend yield near 1.1% offer value for long-term investors amid stable cash flow trends.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Barclays PLC

Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments

Read more on BCS

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX